Fig. 1
From: 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Del(17p) influences the pharmacokinetics of rituximab (RTX). Del(17p) CLL patients have a faster rituximab (RTX) clearance (CL) (a), a lower RTX distribution in the central volume (V1) (c) while peripheral volume (V2) was larger (d), and a significantly lower RTX rate of elimination (Kout) (b) compared to patients presenting other cytogenetic abnormalities. Statistics are indicated when p < 0.05 (Mann-Whitney U test)